Clinically Relevant Pharmacogenomic Testing in Pediatric Practice
Authors:
- 6 May 2014
- journal article
- research article
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 53 (9) , 831-838
Abstract
Clinicians and patients continue to convey interest in personalized medicine. The objective of personalized medicine is to improve healthcare by tailoring disease prevention, diagnosis, and treatment strategies for individuals based on their unique clinical history and genetic composition. This article offers an overview of pharmacogenomics, discusses caveats specific to pharmacogenomics in pediatric populations, provides evidence-based recommendations for pediatric clinicians, and offers insight regarding the future role of pharmacogenomics testing in pediatric medicine. Reviews of the current literature and thoughtful discussions are presented regarding the pharmacogenomics of antidepressants, codeine and oncologic, asthma, and immunomodulatory pharmacotherapies.Keywords
This publication has 21 references indexed in Scilit:
- Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal TransplantationTherapeutic Drug Monitoring, 2013
- A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemiaThe Pharmacogenomics Journal, 2012
- Psychiatric Pharmacogenomics in Pediatric PsychopharmacologyChild and Adolescent Psychiatric Clinics of North America, 2012
- Personalized medicine in pediatric cardiologyCurrent Opinion in Pediatrics, 2012
- Pharmacogenomics in pediatric rheumatologyCurrent Opinion in Rheumatology, 2012
- Variation at GLCCI1 and FCER2 : One Step closer to Personalized Asthma TreatmentPharmacogenomics, 2012
- Pharmacogenomics in pediatric leukemiaCurrent Opinion in Pediatrics, 2010
- Immunosuppression Therapy for Pediatric Heart TransplantationCurrent Treatment Options in Cardiovascular Medicine, 2010
- Treatment Heterogeneity in AsthmaMolecular Diagnosis & Therapy, 2007
- Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein β3 subunit as predictors of response to fluoxetine and nortriptylineInternational Journal of Neuropsychopharmacology, 2003